Trials / Completed
CompletedNCT01215513
Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients Requiring Androgen Ablation Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-centre single arm trial to investigate long-term safety and tolerability of degarelix in Korean patients with prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Degarelix |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2010-10-06
- Last updated
- 2013-05-22
- Results posted
- 2013-05-22
Locations
11 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01215513. Inclusion in this directory is not an endorsement.